What is the 13F Pro Quality Score for STTK?

13F Pro ranks Shattuck Labs, Inc. (STTK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STTK's current score at https://13fpro.ai/research/STTK (free sign-up required for the full ranking).

Which hedge funds own the most STTK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of STTK include ORBIMED ADVISORS, Redmile Group,, Prosight Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/STTK as soon as new 13F filings post.

Where does 13F Pro source STTK data?

All Shattuck Labs, Inc. fundamentals and ownership data come directly from SEC EDGAR. Shattuck Labs, Inc. files with the SEC under CIK 1680367. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STTK in?

Shattuck Labs, Inc. (STTK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STTK research updated on 13F Pro?

STTK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Shattuck Labs, Inc.(STTK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1680367 STTK stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

STTK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Shattuck Labs, Inc. (STTK), a Healthcare sector company. STTK is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Shattuck Labs, Inc. reports net income of $-14.8M, free cash flow of $-13.4M. Top institutional holders of STTK by reported 13-F value include ORBIMED ADVISORS, Redmile Group,, Prosight Management,, based on the most recent SEC filings. STTK trades on the Nasdaq exchange and files with the SEC under CIK 1680367. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STTK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Shattuck Labs, Inc. directly from SEC EDGAR. Shattuck Labs, Inc.'s 13F Pro composite quality score has ranged between 3 and 27 since 2021, currently 22.8 — an improving long-term trajectory across 16 quarterly and live scoring snapshots.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-14.8M

Free Cash Flow

Q1 2026

$-13.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+245.3% YoY

$5.7MFY 2024

FY21 $30.0MFY22 $652.0KFY23 $1.7MFY24 $5.7M

Net Income

+13.6% YoY

$-75.4MFY 2024

FY21 $-45.0MFY22 $-101.9MFY23 $-87.3MFY24 $-75.4M

Operating Income

+12.4% YoY

$-80.6MFY 2024

FY21 $-45.3MFY22 $-103.3MFY23 $-92.0MFY24 $-80.6M

EPS (Diluted)

+27.3% YoY

$-1.49FY 2024

FY21 $-1.07FY22 $-2.41FY23 $-2.05FY24 $-1.49

Total Assets

-42.9% YoY

$91.0MFY 2024

FY21 $298.6MFY22 $205.3MFY23 $159.6MFY24 $91.0M

Op. Cash Flow

+25.5% YoY

$-60.5MFY 2024

FY21 $-57.1MFY22 $-94.5MFY23 $-81.2MFY24 $-60.5M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$5.7M +245.3%	$1.7M +154.1%	$652.0K -97.8%	$30.0M +202.2%	$9.9M
Net Income	$-75.4M +13.6%	$-87.3M +14.4%	$-101.9M -126.7%	$-45.0M -22.9%	$-36.6M
Operating Income	$-80.6M +12.4%	$-92.0M +11.0%	$-103.3M -128.3%	$-45.3M -22.6%	$-36.9M
EPS (Diluted)	$-1.49 +27.3%	$-2.05 +14.9%	$-2.41 -125.2%	$-1.07 +54.7%	$-2.36
Total Assets	$91.0M -42.9%	$159.6M -22.3%	$205.3M -31.2%	$298.6M -14.4%	$349.0M
Operating Cash Flow	$-60.5M +25.5%	$-81.2M +14.0%	$-94.5M -65.4%	$-57.1M -69.7%	$-33.7M

AI Insight: STTK Financial Trends

Equity rebounded to $96M in Q1 2026 — likely a capital raise — but zero revenue and persistent $13–16M quarterly losses keep the burn clock ticking.

• Revenue has been effectively zero since Q4 2024, down from $3M in Q3 2024, signaling no commercial traction.

• Operating losses narrowed from -$23M in Q2 2024 to -$11M in Q3 2025, but re-widened to -$16M in Q1 2026.

• Equity jumped from $57M in Q2 2025 to $93M in Q3 2025, suggesting a capital infusion extended the runway.

• Operating cash outflow has ranged -$8M to -$17M per quarter; no debt reported, limiting near-term insolvency risk.

⚠ Equity is $96M against ~$12M quarterly cash burn — implying roughly 2 years of runway without additional financing.

⚠ Operating losses re-accelerated to -$16M in Q1 2026 after reaching a low of -$11M in Q3 2025 — trend reversal to monitor.

⚠ Any resumption of collaboration revenue (as seen in Q2–Q3 2024) would be a meaningful positive inflection to watch.

AI Insight: STTK Ratio Trends

Return metrics remain deeply negative but have sharply recovered from Q4 2024 trough, with ROIC improving from -98.7% to -64.9% by Q1 2026.

• ROIC hit a trough of -98.7% in Q4 2024, then recovered to -64.9% in both Q4 2025 and Q1 2026.

• ROA improved from -82.1% in Q4 2024 to -57.8% in Q1 2026, suggesting reduced cash burn relative to assets.

• TTM ROE, ROA, and ROIC of -52.0%, -48.8%, and -54.9% remain deeply negative, reflecting a pre-revenue clinical-stage company.

⚠ OpMargin, NPM, and D/E are entirely absent across all periods — limits visibility into cost structure and leverage.

⚠ Q3 2025 showed the sharpest single-quarter improvement (-46.0% ROIC); watch whether Q2 2026 sustains this trajectory or reverts.

Get alerted when STTK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Shattuck Labs, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STTK

ORBIMED ADVISORS LLC
$40.5M6,306,127 sh
Redmile Group, LLC
$35.6M5,539,724 sh
Prosight Management, LP
$32.2M5,004,439 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$29.9M4,644,957 sh
NEXTBio Capital Management LP
$20.3M3,149,907 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.6M2,277,176 sh
CLARK ESTATES INC/NY
$9.5M1,475,648 sh
PINNACLE ASSOCIATES LTD
$8.8M1,368,223 sh
abrdn plc
$7.5M1,159,321 sh
Point72 Asset Management, L.P.
$6.6M1,031,049 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$40.5M	6,306,127
Redmile Group, LLC	$35.6M	5,539,724
Prosight Management, LP	$32.2M	5,004,439
ADAGE CAPITAL PARTNERS GP, L.L.C.	$29.9M	4,644,957
NEXTBio Capital Management LP	$20.3M	3,149,907
VANGUARD CAPITAL MANAGEMENT LLC	$14.6M	2,277,176
CLARK ESTATES INC/NY	$9.5M	1,475,648
PINNACLE ASSOCIATES LTD	$8.8M	1,368,223
abrdn plc	$7.5M	1,159,321
Point72 Asset Management, L.P.	$6.6M	1,031,049

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STTK on your watchlist

Track score changes the day Shattuck Labs, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STTK a good stock to buy?

13F Pro's AI-powered analysis of Shattuck Labs, Inc. (STTK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STTK are available on the STTK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own STTK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STTK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Shattuck Labs, Inc.'s investment landscape.